Evidence map›Paper›PMID 38969342›Full record

ArticleCancer discovery2024

Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer.

Ryan N Serio, Armin Scheben, Billy Lu, Domenic V Gargiulo, Lucrezia Patruno, Caroline L Buckholtz, Ryan J Chaffee, Megan C Jibilian, Steven G Persaud, Stephen J Staklinski and 6 more

Abstract read
In one paragraph

Article in Cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ryan N SerioMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-5804-5979
Armin SchebenSimons Center for Quantitative Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.ORCID 0000-0002-2230-2013
Billy LuDepartment of Pharmacology, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-7396-2783
Domenic V GargiuloDepartment of Pharmacology, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-8833-4894
Lucrezia PatrunoDepartment of Informatics, Systems and Communication, University of Milano-Bicocca, Milan, Italy.ORCID 0000-0002-3721-9984
Caroline L BuckholtzMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-5676-905X
Ryan J ChaffeeMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0009-0008-1364-6499
Megan C JibilianMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0009-0009-7759-519X
Steven G PersaudMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0009-0003-4673-1706
Stephen J StaklinskiSimons Center for Quantitative Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.ORCID 0000-0002-1746-6320
Rebecca HassettSimons Center for Quantitative Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.ORCID 0000-0001-5133-9387
Lise M BraultMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-8698-3161
Daniele RamazzottiDepartment of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.ORCID 0000-0002-6087-2666
Christopher E BarbieriMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0381-1947
Adam C SiepelSimons Center for Quantitative Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.ORCID 0000-0002-3557-7219
Dawid G NowakMeyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-4910-8963

Funding

Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI David A Tuveson · 1987 to 2026
$118.9M
Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional RegulationR35GM127070 · NIGMS · COLD SPRING HARBOR LABORATORY · PI Adam Charles Siepel · 2018 to 2026
$4.7M
"Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis"R01CA272466 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Dawid Grzegorz Nowak · 2023 to 2026
$2.5M
Predoctoral Training in Pharmacological SciencesT32GM141949 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Kristen Elizabeth Pleil · 2021 to 2026
$2.5M
Molecular and Translational Oncology ResearchT32CA203702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN, GIANNAKAKOU, PARASKEVI · 2017 to 2021
$1.4M
American Cancer Society (ACS) Research Scholar GrantCancer Research UK (CRUK) 22790Department of Defense Education Activity (DoDEA) W81XWH-22-1-0068Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 22790National Cancer Institute (NCI) R01-CA272466National Cancer Institute (NCI) T32CA203702National Institutes of Health (NIH) 1T32GM141949National Institutes of Health (NIH) 5T32GM141949National Institutes of Health (NIH) R35-GM127070NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA272466NCI NIH HHS T32 CA203702NIGMS NIH HHS R35 GM127070NIGMS NIH HHS T32 GM141949Starr Foundation (TSF) Centennial Scholarship
6 · The paper itself

Abstract

The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model-EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site. Significance: Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).

Indexed as

Neoplasm MetastasisProstatic NeoplasmsAnimalsCell MovementDisease Models, AnimalHumansMaleMice

Identifiers

PMID38969342
PMCPMC11984259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.